MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY

Abstract. Immune status has been studied in 111 patients with breast malignancies following reconstructive surgery. Clinical and laboratory features of secondary immune insufficiency were determined during post-surgical period. The immune status of the studied patients was characterized by the marke...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. A. Karpov, A. S. Simbirtsev
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	betaleukin bestim reconstructive surgery Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/bd16017ee3c34144b13565487c5a452b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd16017ee3c34144b13565487c5a452b
record_format	dspace
spelling	oai:doaj.org-article:bd16017ee3c34144b13565487c5a452b2021-11-18T08:03:39ZMAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY1563-06252313-741X10.15789/1563-0625-2008-4-5-449-454https://doaj.org/article/bd16017ee3c34144b13565487c5a452b2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/214https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Immune status has been studied in 111 patients with breast malignancies following reconstructive surgery. Clinical and laboratory features of secondary immune insufficiency were determined during post-surgical period. The immune status of the studied patients was characterized by the marked absolute and relative lymphocytopenia associated with significantly decreased number of CD3+ and HLA-DR+ cells. Pronounced neutrophilia was accompanied by increased spontaneous NBT-reducing activity. Recombinant IL-1 (Betaleukin®) and a new synthetic dipeptide «Bestim» were used for immunotropic therapy. While studying clinical and immunological efficiency of the drugs, it was established that the patients receiving immunotherapy had significantly lower complication rates (resp., 13.33% and 17.64%) than the patients in comparison group (48.43%). A difference for the rates of purulent inflammatory complications was statistically significant. A trend to better survival of grafts and transplants was noted following the course of immunotherapy. Application of Betaleukin and «Bestim» in combined treatment protocols resulted into a significant reduction of hospital staying and decreased duration of antibacterial therapy. These drugs showed a pronounced immunostimulating effect: absolute and relative lymphocyte contents were increased, the number of CD3+ and CD4+ lymphocytes was maintained within the normal range, whereas a significant decrease of these key values was observed in the comparison group. Following a course of immunotherapeutic drugs, normal levels of certain cytokines were noted, some imbalance of cytokine values being observed in the comparison group. After treatment with «Bestim», increased IL-2 and decreased IL-4 levels were revealed. Hence, Betaleukin and «Bestim» display clinical and immunologic efficiency in management of the patients with malignant breast tumors following reconstructive surgery. (Med. Immunol., vol. 10, N 4-5, pp 449-454).I. A. KarpovA. S. SimbirtsevSPb RAACIarticlebetaleukinbestimreconstructive surgeryImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 10, Iss 4-5, Pp 449-454 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	betaleukin bestim reconstructive surgery Immunologic diseases. Allergy RC581-607
spellingShingle	betaleukin bestim reconstructive surgery Immunologic diseases. Allergy RC581-607 I. A. Karpov A. S. Simbirtsev MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
description	Abstract. Immune status has been studied in 111 patients with breast malignancies following reconstructive surgery. Clinical and laboratory features of secondary immune insufficiency were determined during post-surgical period. The immune status of the studied patients was characterized by the marked absolute and relative lymphocytopenia associated with significantly decreased number of CD3+ and HLA-DR+ cells. Pronounced neutrophilia was accompanied by increased spontaneous NBT-reducing activity. Recombinant IL-1 (Betaleukin®) and a new synthetic dipeptide «Bestim» were used for immunotropic therapy. While studying clinical and immunological efficiency of the drugs, it was established that the patients receiving immunotherapy had significantly lower complication rates (resp., 13.33% and 17.64%) than the patients in comparison group (48.43%). A difference for the rates of purulent inflammatory complications was statistically significant. A trend to better survival of grafts and transplants was noted following the course of immunotherapy. Application of Betaleukin and «Bestim» in combined treatment protocols resulted into a significant reduction of hospital staying and decreased duration of antibacterial therapy. These drugs showed a pronounced immunostimulating effect: absolute and relative lymphocyte contents were increased, the number of CD3+ and CD4+ lymphocytes was maintained within the normal range, whereas a significant decrease of these key values was observed in the comparison group. Following a course of immunotherapeutic drugs, normal levels of certain cytokines were noted, some imbalance of cytokine values being observed in the comparison group. After treatment with «Bestim», increased IL-2 and decreased IL-4 levels were revealed. Hence, Betaleukin and «Bestim» display clinical and immunologic efficiency in management of the patients with malignant breast tumors following reconstructive surgery. (Med. Immunol., vol. 10, N 4-5, pp 449-454).
format	article
author	I. A. Karpov A. S. Simbirtsev
author_facet	I. A. Karpov A. S. Simbirtsev
author_sort	I. A. Karpov
title	MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
title_short	MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
title_full	MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
title_fullStr	MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
title_full_unstemmed	MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY
title_sort	mammary reconstructive surgery following mastectomy: efficiency and prospectives for immunotropic therapy
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/bd16017ee3c34144b13565487c5a452b
work_keys_str_mv	AT iakarpov mammaryreconstructivesurgeryfollowingmastectomyefficiencyandprospectivesforimmunotropictherapy AT assimbirtsev mammaryreconstructivesurgeryfollowingmastectomyefficiencyandprospectivesforimmunotropictherapy
_version_	1718422565177786368

MAMMARY RECONSTRUCTIVE SURGERY FOLLOWING MASTECTOMY: EFFICIENCY AND PROSPECTIVES FOR IMMUNOTROPIC THERAPY

Ejemplares similares